# Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

> **NCT01611259** · PHASE2 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 50 (actual)

## Conditions studied

- Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

## Interventions

- **DRUG:** Rituximab and Lenalidomide

## Key facts

- **NCT ID:** NCT01611259
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-05
- **Final completion:** 2015-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01611259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01611259, "Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01611259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*